GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (NAS:NBIX) » Definitions » EPS (Diluted)
中文

Neurocrine Biosciences (Neurocrine Biosciences) EPS (Diluted) : $2.42 (TTM As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences EPS (Diluted)?

Neurocrine Biosciences's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $1.44. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.42.

Neurocrine Biosciences's EPS (Basic) for the three months ended in Dec. 2023 was $1.50. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.54.

Neurocrine Biosciences's EPS without NRI for the three months ended in Dec. 2023 was $1.54. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $4.00.

During the past 12 months, Neurocrine Biosciences's average EPS without NRIGrowth Rate was 118.80% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -11.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 61.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Neurocrine Biosciences's highest 3-Year average EPS without NRI Growth Rate was 145.70% per year. The lowest was -58.60% per year. And the median was -14.35% per year.


Neurocrine Biosciences EPS (Diluted) Historical Data

The historical data trend for Neurocrine Biosciences's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences EPS (Diluted) Chart

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 4.16 0.92 1.56 2.47

Neurocrine Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 -0.79 0.95 0.82 1.44

Competitive Comparison of Neurocrine Biosciences's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's PE Ratio falls into.



Neurocrine Biosciences EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Neurocrine Biosciences's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(249.7-0)/101.000
=2.47

Neurocrine Biosciences's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(147.7-0)/102.200
=1.45

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurocrine Biosciences  (NAS:NBIX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Neurocrine Biosciences EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (Neurocrine Biosciences) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Executives
Kevin Charles Gorman officer: Sr VP, Business Development 12790 EL CAMINO REAL, SAN DIEGO CA 92130
William H Rastetter director 9885 TOWNE CENTRE DR., SAN DIEGO CA 92121
Kyle Gano officer: Chief Business Dev Officer NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Eiry Roberts officer: Chief Medical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Julie Cooke officer: Chief Human Resources Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Gary A Lyons director, officer: President and CEO 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Darin Lippoldt officer: Chief Legal Officer C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Jude Onyia officer: Chief Scientific Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
David W. Boyer officer: Chief Corp. Affairs Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Ingrid Delaet officer: Chief Regulatory Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Matt Abernethy officer: Chief Financial Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121
Eric Benevich officer: Chief Commerical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Malcolm Lloyd-smith officer: Chief Regulatory Officer 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080